Pacific Biosciences Of California (PACB) Total Liabilities (2010 - 2026)

Pacific Biosciences Of California has reported Total Liabilities for 17 years, with the latest figure at $780.0 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 1.41% year-over-year to $780.0 million; the trailing twelve-month figure through Mar 2026 stood at $780.0 million (up 1.41% YoY), and the FY2025 full-year result was $778.7 million, up 3.3% from the prior year.
• Total Liabilities for Q1 2026 stood at $780.0 million, roughly flat from $778.7 million in the prior quarter.
• The five-year high for Total Liabilities was $1.2 billion in Q2 2023, with the low at $753.9 million in Q4 2024.
• Average Total Liabilities over 5 years is $1.0 billion, with a median of $1.0 billion recorded in 2024.
• Year-over-year, Total Liabilities grew 23.63% in 2022 and retreated 27.84% in 2024.
• Tracing PACB's Total Liabilities over 5 years: stood at $1.2 billion in 2022, then slipped by 13.24% to $1.0 billion in 2023, then dropped by 27.84% to $753.9 million in 2024, then climbed by 3.3% to $778.7 million in 2025, then gained by 0.16% to $780.0 million in 2026.
• The last three Total Liabilities figures came in at $780.0 million (Q1 2026), $778.7 million (Q4 2025), and $767.1 million (Q3 2025), per Business Quant data.

Peer Comparison